NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis $4.15 +0.06 (+1.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.08▼$4.2050-Day Range$3.19▼$4.3052-Week Range$1.42▼$8.38Volume199,899 shsAverage Volume471,495 shsMarket Capitalization$246.55 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aldeyra Therapeutics alerts: Email Address Aldeyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.9% Upside$9.33 Price TargetShort InterestBearish4.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.23 out of 5 starsMedical Sector788th out of 936 stocksPharmaceutical Preparations Industry367th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aldeyra Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.56% of the outstanding shares of Aldeyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 2.0 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aldeyra Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.50% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aldeyra Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aldeyra Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Aldeyra Therapeutics Stock (NASDAQ:ALDX)Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More ALDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALDX Stock News HeadlinesJune 20, 2024 | businesswire.comAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableJune 13, 2024 | businesswire.comAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 12, 2024 | businesswire.comAldeyra Therapeutics to Host Investor Roundtable Q&AMay 29, 2024 | businesswire.comAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 8, 2024 | businesswire.comAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseMay 3, 2024 | investorplace.comALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024April 25, 2024 | businesswire.comAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.April 18, 2024 | businesswire.comAldeyra Therapeutics to Host Research & Development Day on April 25, 2024April 15, 2024 | markets.businessinsider.comAttention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors: Grabar Law Office Is Investigating Claims on Your BehalfApril 10, 2024 | investing.comPerceptive advisors buys Aldeyra Therapeutics shares worth $833kApril 4, 2024 | msn.comAldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingApril 3, 2024 | msn.comAldeyra gains as Oppenheimer upgrades on revised plans for lead assetApril 3, 2024 | finance.yahoo.comAldeyra's Dry Eye Disease Drug May Be on Path for FDA ApprovalApril 3, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The CornerApril 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)March 13, 2024 | finance.yahoo.comAldeyra Therapeutics Inc President and CEO Todd Brady Sells Company SharesSee More Headlines Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+124.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.69% Return on Assets-20.26% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio6.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book2.03Miscellaneous Outstanding Shares59,410,000Free Float54,364,000Market Cap$246.55 million OptionableOptionable Beta1.45 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsNature's Sunshine ProductsNASDAQ:NATRVerrica PharmaceuticalsNASDAQ:VRCAVerastemNASDAQ:VSTMNextCureNASDAQ:NXTCVYNE TherapeuticsNASDAQ:VYNEView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 34,885 shares on 7/26/2024Ownership: 0.329%Hennion & Walsh Asset Management Inc.Bought 6,944 shares on 7/20/2024Ownership: 0.148%Diversified Trust CoBought 12,265 shares on 7/16/2024Ownership: 0.021%SG Americas Securities LLCBought 11,378 shares on 7/12/2024Ownership: 0.019%Woodstock CorpBought 10,091 shares on 7/8/2024Ownership: 0.304%View All Insider TransactionsView All Institutional Transactions ALDX Stock Analysis - Frequently Asked Questions How have ALDX shares performed this year? Aldeyra Therapeutics' stock was trading at $3.51 on January 1st, 2024. Since then, ALDX stock has increased by 18.2% and is now trading at $4.15. View the best growth stocks for 2024 here. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. Who are Aldeyra Therapeutics' major shareholders? Aldeyra Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.33%), Woodstock Corp (0.30%), Hennion & Walsh Asset Management Inc. (0.15%) and Diversified Trust Co (0.02%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Bruce Greenberg and Martin Joseph Joyce. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Zosano Pharma (ZSAN). This page (NASDAQ:ALDX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
